Contents

Glossary

1. Preliminary matters

• • 1.7.1 Operations/Policies of the Committee
    • 1.7.1.1 Item deleted
      • 1.7.1.2.1 Item deleted
      • 1.7.1.2.2 Item deleted
      • 1.7.1.2.3 Item deleted
      • 1.7.1.2.4 Item deleted
    • 1.7.1.3 Copyright references in scheduling submissions
    • 1.7.1.4 Item deleted
• 1.8 NDPSC working parties
  • 1.8.1 Trans-Tasman Harmonisation Working Party
    • 1.8.1.1 Cadmium compounds and cadmium sulphide
  • 1.8.2 Fluorides working party

2. Proposed changes/additions to Parts 1 to 3 and Part 5 of the Standard for the Uniform Scheduling of Drugs and Poisons

• 2.1 SUSDP, Part 1
  • 2.1.1 Sterioisomer exemption - Levomethorphan and Levorphanol
  • 2.1.2 Interpretation of aerosol cncentration in the SUSDP
  • 2.1.3 Interpretation of external
• 2.2 SUSDP, PART 2
• 2.3 SUSDP, PART 3
  • 2.3.1 Schedule 5/Schedule 6 storage statements
• 2.4 SUSDP, PART 5
  • 2.4.1 Lead in paints & inks and the Uniform Paint Standard (Appendix I)

Top of page

Agricultural/veterinary, industrial and domestic chemicals

3. Matters arising from the Minutes of the previous meeting

4. Other outstanding matters from previous meetings

• 4.1 4-Aminopyridine and metallic phosphide (including zinc phosphide)
• 4.2 Formaldehyde and paraformaldehyde

5. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 5.1 SUSDP, Part 4
  • 5.1.1 Monensin
• 5.2 SUSDP, Part 5

6. Matters referred by the Australian Pesticides and Veterinary Medicines Authority

• 6.1 Metribuzin
• 6.2 Didecyldimethylammonium chloride and didecyldimethylammonium carbonate
• 6.3 Flubendiamide
• 6.4 Prosulfocarb
• 6.5 Mitratapide
• 6.6 Metaflumizone

7. Matters referred by Office of Chemical Safety (OCS)

• 7.1 Castor oil, monomaleate
• 7.2 Methylnorbornylpyridine

8. Other matters for consideration

9. Information items (Ag/vet, industrial & domestic chemicals)

• 9.1 Chemicals and plastics regulation
• 9.2 What is a derivative?

Top of page

Pharmaceuticals

10. Matters arising from the Minutes of the previous meeting

• 10.1 Paracetamol and phenylephrine

11. Other outstanding matters from previous meeting

• 11.1 Pantoprazole
• 11.2 Fractionated and recombinant blood products

12. Proposed changes/additions to the Standard for the Uniform Scheduling of Drugs and Poisons

• 12.1 SUSDP, Part 4
  • 12.1.1 Hyoscine butylbromide
  • 12.1.2 Diclofenac
  • 12.1.3 Paracetamol and morphine
  • 12.1.4 Piper methysticum (kava)
• 12.2 SUSDP, Part 5

13. Matters referred by registration process for Prescription Medicines

• 13.1 New substances (not seen before by NDPSC)
  • 13.1.1 Miglustat
  • 13.1.2 Agomelatine
  • 13.1.3 Zonisamide
• 13.2 For information (substances already scheduled)
  • 13.2.1 Item deleted
  • 13.2.2 Item deleted
  • 13.2.3 Item deleted
  • 13.2.4 Item deleted
  • 13.2.5 Human Papillomavirus Vaccine (HPV)

14. Other matters for consideration

• 14.1 Child resistant packaging
• 14.2 Appendix D

15. Matters referred by the Medicines Evaluation Committee (MEC)

16. Matters referred by the Medicines Classification Committee (MCC) of New Zealand

• 16.1 MCC new medicines
  • 16.1.1 Dabigatran
  • 16.1.2 Methoxamine
  • 16.1.3 Dextromethorphan

17. Minutes of the Adverse Drug Reactions Advisory Committee (ADRAC)

• 17.1 Item deleted

18. Minutes of the Medical Device Evaluation Committee (MDEC)

21. Amendments to the SUSDP

• 21.1 Editorial changes and errata
  • 21.1.1 Editorials and Errata - Formic acid and etretinate
  • 21.1.2 Hydrocortisone
  • 21.1.3 Levamisole
  • 21.1.4 Aminacrine
• 21.2 SUSDP 22 amendment 2 - Variations to dibromopropamine, paracetamol, promethazine, propamidine and trimeprazine